Brandioside



Compound IDCDAMM01831
Common nameBrandioside
IUPAC name[5-acetyloxy-6-[2-(3,4-dihydroxyphenyl)ethoxy]-2-[(3,4,5-trihydroxy-6-methyloxan-2-yl)methoxy]-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-3-yl] 3-(3,4-dihydroxyphenyl)prop-2-enoate
Molecular formulaC37H48O20

Experimental data

Retention time7.79
Adduct[M+H]+
Actual mz813.281
Theoretical mz813.281
Error0.46
Ionizaton modePositive
Instrument typeLC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60
Score6.9545

Identifiers and class information

Inchi keySAUVJZCYCNLQSI-RMKNXTFCNA-N
SmilesO=C(OC1C(OCC2OC(C)C(O)C(O)C2O)OC(OCCC3=CC=C(O)C(O)=C3)C(OC(=O)C)C1OC4OC(C)C(O)C(O)C4O)C=CC5=CC=C(O)C(O)=C5
SuperclassOrganic oxygen compounds
ClassOrganooxygen compounds

Pharmacokinetic properties

Number of descriptor values(#stars)13
Number of non-conjugated amine groups (#amine)0
Number of amidine and guanidine groups (#amidine)0
Number of carboxylic acid groups (#acid)0
Number of non-conjugated amide groups (#amide)0
Number of rotatable bonds (#rotor)24
Number of reactive functional groups (#rtvFG)5
Predicted central nervous system activity (CNS)-2
Molecular weight (mol_MW)812.774
Computed dipole moment(dipole)7.401
Total solvent accessible surface area (SASA)1004.2
Hydrophobic component of SASA (FOSA)446.515
Hydrophilic component of SASA (FISA)365.837
Pie component of the SASA (PISA)191.844
Weakly polar component of the SASA (WPSA)0
Total solvent accesible volume (volume)2143.61
Number of hydrogen bond donors (donorHB)10
Number of hydrogen bond acceptors (accptHB)27.4
Free energy of solvation of dipole (dip^2/V)0.02555
Index of cohesive interaction in solids (ACxDN^.5/SA)0.0862843
Globularity descriptor (glob)0.800651
Predicted polarizability in cubic angstroms (QPpolrz)66.055
Predicted hexadecane/gas partition coefficient (QPlogPC16)23.773
Predicted octanol/gas partition coefficient (QPlogPoct)52.76
Predicted water/gas partition coefficient (QPlogPw)42.27
Predicted octanol/water partition coefficient (QPlogPo/w)-1.543
Predicted aqueous solubility (QPlogS)-1.602
Conformation-independent predicted aqueous solubility (CIQPlogS)-5.006
Predicted IC50 value for blockage of HERG K+ channels (QPlogHERG)-5.673
Predicted apparent Caco-2 cell permeability in nm/sec (QPPCaco)3.363
Predicted brain/blood partition coefficient (QPlogBB)-4.688
Predicted apparent MDCK cell permeability in nm/sec (QPPMDCK)1.049
Predicted skin permeability, log Kp (QPlogKp)-5.282
PM3 calculated ionization potential (IP(ev))8.863
PM3 calculated electron affinity (EA(eV))0.825
Number of likely metabolic reactions (#metab)12
Prediction of binding to human serum albumin (QPlogKhsa)-1.613
Predicted qualitative human oral absorption (HumanOralAbsorption)1
Predicted human oral absorption on 0 to 100% scale (PercentHumanOralAbsorption)0
Solvent-accessible surface area of fluorine atoms (SAFluorine)0
Solvent-accessible surface area of amide oxygen atoms (SAamideO)0
Van der Waals surface area (PSA)317.901
Number of nitrogen and oxygen atoms (#NandO)20
Number of violations of Lipinski’s rule of five (RuleOfFive)3
Number of violations of Jorgensen’s rule of three (RuleOfThree)2

Compound-target network

Cytoscape Graph

Protein targets associated with phytocompound

Uniprot ID Gene name Target name TTD_ID Prediction source
O43570CA12Carbonic anhydrase XIIT16987SEA
Q16790CA9Carbonic anhydrase IXT64567SEA
P02766TTRTransthyretinT86462SEA
P17612PRKACAcAMP-dependent protein kinase alpha-catalytic subunitT12808SwissTargetPrediction
P43166CA7Carbonic anhydrase VIIT37541SEA
P23280CA6Carbonic anhydrase VIT06569SEA
Q9ULX7CA14Carbonic anhydrase XIVT31992SEA
P08253MMP2Matrix metalloproteinase 2T68251SwissTargetPrediction
P39900MMP12Matrix metalloproteinase 12T03500SwissTargetPrediction
P60568IL2Interleukin-2T61698SEA
P04746AMY2APancreatic alpha-amylaseT86918SEA
Q9GZQ4NMUR2Neuromedin-U receptor 2T04210SEA

Target associated diseases

TTD_ID Disease_ID Disease name ICD_11 Uniprot ID Gene names
T16987DI0046Bacterial infection[ICD-11: 1A00-1C4Z]O43570CA12
T16987DI0372Seborrhoeic dermatitis[ICD-11: EA81]O43570CA12
T64567DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]Q16790CA9
T86462DI0026Amyloidosis[ICD-11: 5D00]P02766TTR
T12808DI0279Muscular atrophy[ICD-11: 8B61]P17612PRKACA
T06569DI0046Bacterial infection[ICD-11: 1A00-1C4Z]P23280CA6
T06569DI0372Seborrhoeic dermatitis[ICD-11: EA81]P23280CA6
T31992DI0046Bacterial infection[ICD-11: 1A00-1C4Z]Q9ULX7CA14
T31992DI0204Inborn metabolism deficiency[ICD-11: 5C50-5C59]Q9ULX7CA14
T68251DI0238Lung cancer[ICD-11: 2C25]P08253MMP2
T03500DI0037Asthma[ICD-11: CA23]P39900MMP12
T03500DI0238Lung cancer[ICD-11: 2C25]P39900MMP12
T03500DI0361Renal cell carcinoma[ICD-11: 2C90]P39900MMP12
T61698DI0275Multiple sclerosis[ICD-11: 8A40]P60568IL2
T61698DI0361Renal cell carcinoma[ICD-11: 2C90]P60568IL2
T86918DI0110Cystic fibrosis[ICD-11: CA25]P04746AMY2A
T86918DI0328Pancreatic malfunction[ICD-11: DC30-DC3Z]P04746AMY2A

Copyright © 2025